# DPP4-Inhibitors and Bone Metabolism in Diabetes

> **NCT06770894** · PHASE3 · COMPLETED · sponsor: **Azienda Policlinico Umberto I** · enrollment: 132 (actual)

## Conditions studied

- Osteoporosis
- Bone Loss, Postmenopausal
- Diabetes Mellitus Type 2

## Interventions

- **DRUG:** Sitagliptin 100 mg
- **DRUG:** Placebo Tablets

## Key facts

- **NCT ID:** NCT06770894
- **Lead sponsor:** Azienda Policlinico Umberto I
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-24
- **Primary completion:** 2023-10-10
- **Final completion:** 2024-01-24
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2025-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06770894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06770894, "DPP4-Inhibitors and Bone Metabolism in Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06770894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*